The extent and distribution of biochemical abnormalities thought to reflect disorders of subpopulations of neurons have been determined in the cerebral cortex from brains of patients with Alzheimer-type dementia and depressive illness who died of natural causes. In dementia, loss of gray matter from areas of the parietal and temporal lobes is most obvious. In depression, these areas are not affected, but the pars opercularis and temporal pole are smaller than in controls. Results expressed per unit mass of total protein indicate selective reductions in both disorders of serotonin 2 recognition sites in all areas examined and of somatostatin content in only the temporal pole of the six areas examined. In dementia alone a selective loss was found of somatostatin content of the superior parietal lobule and of serotonin 1A sites and choline acetyltransferase activity in all areas examined. Results for depression expressed per entire area indicate additionally reduced somatostatin content and serotonin 1A sites in the pars opercularis and serotonin 1A sites in the temporal pole. These multiple analyses performed on each sample provide further support for a prominent disorder of pyramidal neurons in dementia as well as more evidence for alterations in cortical neurons in depression, either as a result of the disease itself or its treatment.
It is widely recognized that increasing age is associated with an increased risk of developing Alzheimer disease (AD) and depression. Studies of affective disorders have most commonly implicated a functional deficit in the corticopetal (ascending) monoaminergic systems (1) . The discovery of the corticopetal cholinergic abnormality in AD suggested the basis for a rational pharmacological treatment of dementia, although development has so far had little success (2) . Treatment of depression, especially that in old age, is not always effective (3, 4) . In both conditions, this may be due to failure to correct abnormalities of neurons other than the corticopetal. One histological hallmark ofAD, neurofibrillary degeneration, occurs typically within cortical pyramidal cells and Alzheimer's original report (30) described fewer pyramidal neurons in the cerebral cortex (5) . Pyramidal neurons are difficult to assess biochemically because the probable neurotransmitters, aspartic and glutamic acids, have a ubiquitous distribution and many functions (6) . There is also evidence of structural cortical changes associated with depressive illness (7, 8) . This includes computerized tomographic studies reporting sulcal widening and increases in cerebroventricular size in some depressive patients. With advances in other in vivo brain imaging techniques, such as magnetic resonance imaging and positron emission tomography, knowledge of cortical neuronal systems affected soon after the emergence of clinical symptoms is likely to improve in the future (5, 8) . However, it is necessary to have some postmortem biochemical data to provide a focus for the best use of these techniques of limited availability (8, 9) . Some biochemical measures are probably sensitive to cerebral atrophy. This is because the practice of reporting results relative to unit mass (e.g., per mg of protein) does not make allowance for any reduction in volume of brain structures. Shrinkage or loss of some structures, without change in others, may lead to the reporting of an increase in the indices ofthe unaffected structure and, perhaps more importantly, an apparently small decrease in markers of the affected structures. Loss of a marker may be considerably underestimated, should the structure to which it relates represent a large proportion of tissue volume, such as pyramidal neurons within the cerebral cortex. Similarly, should losses occur equally in all structures (e.g., of pyramidal neurons and associated structures organized in columns) there may be no change reported even in severely atrophied tissue (6, 10) .
We have investigated cortical pathology in AD and depressive patients using several techniques. Somatostatin content is a reliable postmortem marker of one type of cortical y-aminobutyric acid-releasing interneuron (9, 10) and together with y-aminobutyric acid has been implicated in depression (11, 12) . Choline acetyltransferase (ChAT) activity is reduced in AD, possibly secondary to degeneration of cortical pyramidal neurons (13) . Binding of 8-[3H]hydroxy-2-(di-n-propylamino)tetralin (Amersham) to serotonin (5-HT) 1A recognition sites may also index pyramidal neurons (14) (15) (16) (17) 6 AD, and 12 control subjects (Table 1) were used, with no selection by disease severity or agonal state. No subject has microscopic evidence of more than slight cerebrovascular disease. Clinical and histopathological data indicated that the control group was free of gross psychiatric or neurological disorders.
Brain Dissection and Assays. On removal from the skull, one hemisphere was sealed in a polyethylene bag and stored at -70'C. After being warmed to -10'C for 12 hr, it was cut into 5-mm-thick coronal slices. Cortical areas, identified according to brain anatomy, were dissected on a cooled tray (-20°C) 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. tNo sulcal widening or white matter loss, whereas three of the other depressive subjects showed these to a slight degree including the bipolar disorder (white matter loss of a moderate degree). Mean age and autopsy delay of AD and depressive subjects were not significantly different from control.
mixed to create a homogeneous sample containing all cortical layers. Representative aliquots ofthis (M10o ofeach sample) were homogenized in appropriate medium for the determination of total protein (colorimetrically using bovine serum albumin as standard), ChAT activity (radiochemically), somatostatin (radioimmunoassay), and 5-HT sites on membranes (whole particulate) as described (5, 15, 18, 21) . Total and nonspecific binding were determined at one concentration (1 nM) of 3H-labeled ligand close to the affinity constant for control samples, which provides sufficient radioactivity for a reliable estimate of specific binding. Assays were also performed in the presence of unlabeled ligand at a concentration (2 nM) shown (15) (18) were dissected from the brains and weighed. Six areas were assayed (Tables  2 and 3) .
Influence of Pre-and Postmortem Variables. Only 33% of AD subjects had sudden deaths, so protracted terminal illness was overrepresented in this group. However, ChAT activity, somatostatin content, and binding to the 5-HT1A recognition site have been found to be independent of mode of death, and binding to the 5-HT2 recognition site may be dependent upon this in only a few regions (5, 9, 14, 15) . Control and AD subjects were divided according to mode of death but there appeared to be no effect for any variable of a magnitude comparable to that of AD, albeit the numbers of cases were small. The controls showed a significant correlation between age and the weight of gray matter of the para-central gyrus of the frontal lobe, Rs = -0.79 (P < 0.002). There were no other significant correlations with age. Delay to autopsy of controls was not significantly correlated with the weight of gray matter or any biochemical measure. The influence of sex and laterality, assessed in controls, showed only one effect, the weight ofgray matter ofthe lingular gyrus offemales was 81% (P < 0.01) of the value for males. Few results for the depressive subject not given electroconvulsive therapy were outside the confidence interval (mean ± 2 SD of the value for the other subjects) of those that had received this treatment. Lack of treatment was associated with a lower somatostatin content and ChAT activity of gray matter from the temporal pole, with higher binding to 5-HTlA sites in gray matter from the superior parietal lobule and orbital gyrus, and with a greater amount of gray matter in the angular gyrus (data not shown). Values for the AD subjects that had not received medication were within the range of values for the treated 215 ± 28 Data are mean ± SD for 12 controls, 7 depressives, and 6 AD subjects. Kruskal-Wallis one-way ANOVA and the two-tailed Mann-Whitney U test were used to calculate differences from the control: *P < 0.005. tp < 0.001. 
g). Areas not affected in the disorders (data not shown) are all regions of
occipital lobe (superior occipital lobule, lateral occipital lobule, and cuneus and lingular gyrus), most areas offrontal lobe (middle frontal, inferior frontal, pre-central and para-central gyri), and some of parietal lobe (post-central, para-central, and angular gyri). Parahippocampal gyri of controls have weights and protein contents between 3.25 and 8.54 g and between 0.27 and 0.63 g, respectively. These are comparable with short illness depressive subjects (between 4.40 and 5.82 g and between 0.32 and 0.45 g, respectively) but are higher than those with long illness including the bipolar disorder (between 1.79 and 3.06 g and between 0.13 and 0.22 g, respectively). None of the other 23 regions studied showed this effect (data not shown). Although it is realized that the relations of anatomical landmarks may be distorted in atrophied brains, in general the gross anatomy of the cortex was found to be preserved. Protein content of gray matter is expressed per entire region [g of protein per g (wet weight) multiplied by wet weight of region in g]. 5-HT1A site Scatchard analysis (eight ligand concentrations, 0.25-5 nM; parietal lobule) gave KD (nM) and Bmax (fmol/mg of protein) values for 6 AD and 5 matched (18) controls, in parentheses, of 4.0 ± 0.9 (1.8 ± 0.6) and 41.0 ± 9.6 (62.4 ± 8.4), respectively (AD vs. control, P < 0.01, Mann-Whitney U test). Bipolar disorder subject has anomalous somatostatin value not included in the analysis (672 fmol/mg for orbital gyrus). ND, not determined. Kruskal-Wallis one-way ANOVA and the two-tailed Mann-Whitney U test were used to calculate differences from the control: *p < 0.05. tp < 0.02. tP < 0.01. §P < 0.005. ¶p < 0.001.
cases. Data for the AD subject that had received substantial medication were within the confidence interval calculated for the other AD subjects except for the somatostatin content of the parietal lobule and binding to 5-HT2 sites in the orbital gyrus and pars opercularis (less in the treated subject, data not shown). Values for the subject with bipolar disorder were within the confidence interval calculated for those with major depressive disorder except for the somatostatin content of one area (Table 3 ) and the weight of gray matter in the region of Brodmann area (BA) 37 (less in bipolar disorder, data not shown).
Influence of Neuropsychiatric Disorder on Determinations. Table 2 shows the weight of the gray matter of each lobe and the cingulate gyrus. No value of depressive subjects was significantly different from control subjects, whereas weight loss occurred in AD, mainly from the temporal-parietal areas. Differences between AD and control subjects in the weight of gray matter occurred in 10 circumscribed areas of cortex, while differences between depressive and control subjects were apparent in only 3 of the 24 areas, the pars opercularis, temporal pole, and parahippocampal gyrus (Table 3). Maps of the changes are in Fig. 1 . mg of protein were reduced in AD but not in depressive subjects. Scatchard analysis of this showed fewer sites of lower affinity in AD (Table 3) . Somatostatin content per mg of protein was not reduced in the disorders except in the temporal pole (and parietal lobule in AD), whereas binding to 5-HT2 sites was reduced without exception. All differences in recognition sites of depressive subjects appeared to be due to the presence of fewer sites, with the exception of the 5-HT2 site in the temporal pole where the affinity was apparently lower (P < 0.01, data not shown). Table 4 shows that binding to the 5-HT1A recognition site as well as somatostatin content is reduced in depression when allowance is made for the smaller pars opercularis and temporal pole. Mean ChAT activity of these regions were reduced by 72-73% and 30-35% in AD and depressive subjects, respectively. Only the difference in AD was significant (P < 0.005, data not shown). Large differences in all regions assayed for ChAT activity were apparent in AD but not in depressive subjects. These and other results are shown schematically in Fig. 2 . The maps are based on Table 4 and similar data (not shown; subjects and method of calculation and statistical analysis are as in Table 4 ).
DISCUSSION
Specific biochemical indices of a pyramidal neurons in the cerebral cortex have not been established for either postmortem or in vivo imaging studies ofhuman brain. This is because little is known of the biochemical changes induced by loss of either pyramidal cells giving rise to corticofugal, commissural, and corticocortical projections or intrinsic interneurons. One reason is that a technique has not been developed for destroying pyramidal neurons selectively in the cerebral cortex of laboratory animals. Binding site data could also be difficult to interpret due to the complexity of some receptors and the possibility that not all constituent recognition sites are equally affected (6, 11) . Hence, inferences drawn here about the possible role of pyramidal neurons in the present disorders are based on imperfect markers. The losses of cortical gray matter may reflect shrinkage and fallout of pyramidal neurons, as these constitute the major neuronal type (6, 18) , whereas reduced binding to the 5-HT1A site may index loss of a subpopulation of these cells (16) .
The reductions in weight of the gray matter and binding to the 5-HT1A recognition site in AD support the proposal (13) that pyramidal neurons in the parietal and temporal lobes selectively degenerate in this disorder. Losses of binding to the 5-HT1A recognition site expressed per unit mass are apparently more widespread in this series than have been reported (14, 15) in younger patients. However, brain tissue loss is greatest in the youngest AD subjects (22) , so the extent of overall loss of the site may be comparable in the two groups. Cortical interneurons may also degenerate quite widely as reductions in binding to the 5-HT2 recognition site in AD have now been found in the pars opercularis in addition (Table 2) , although the group sizes are relatively small. The absence of change, in general, of either gravimetric or biochemical determinations in these depressive subjects who had died of natural causes, often after an illness lasting many years, is evidence that cortical degeneration is not widespread in this condition. This conclusion is supported by a previous study (23) of nonsuicide depressive subjects where no difference was found in somatostatin content of cortex from unspecified areas of the frontal, temporal, and occipital lobes, although no study to date has examined the temporal pole of depressive subjects. The present results demonstrate peptide loss here that may be related to the decreased concentration of the peptide in cerebrospinal fluid of depressive subjects (12, 24) . Our attempt to measure changes in protein content and binding to Data are mean ± SD. Regions, method of calculation, and subjects are defined in Table 3 . Kruskal-Wallis one-way ANOVA and the two-tailed Mann-Whitney U test were used to calculate differences from the control: *P < 0.05. tP < 0.005. *p < 0.001. the 5-HT1A recognition site of entire areas suggests that corticocortical connections between the temporal pole and frontal lobe (25) , as well as interneurons, have degenerated in these depressives. Corticopetal cholinergic projections appear to be unaffected. Previous studies have reported reduced binding to 5-HT2 (26) and the total population of 5-HT1 (27) sites in the hippocampus of antidepressant-free suicide victims. Only one other study has determined binding to a 5-HT site in a group of elderly depressive subjects dying of natural causes. McKeith et al. (28) reported a tendency toward increased 5-HT2 sites per unit mass in the frontal pole, whereas in our series binding to the site was assayed in four other areas and was found to be significantly reduced. In two of these there is evidence of structural damage. Gray matter of the pars opercularis and temporal pole is reduced in weight, and in the temporal pole somatostatin content per unit mass is reduced.
This study provides further support for a prominent disorder of pyramidal neurons in AD. In addition there is now more evidence for a disorder of cortical neurons in depressed patients. However, the depressive subjects had all received chronic treatment with antidepressants and most electroconvulsive therapy, and these treatments are known to alter numbers of 5-HT recognition sites (for review, see ref. 26 ). The influence of these treatments on the other parameters studied here is unknown, and it remains possible that the changes in the depressive subjects are treatment-rather than disease-related. Nonetheless, the fact that either the disease or its treatment is associated with alterations in several different biochemical markers of cortical neurons, and structural changes in the cerebral cortex are suggested by other techniques (7, 8, 29) , indicates that the role of these cells in the pathogenesis of depression warrants further study. Such an inquiry would benefit from an animal model of subtotal neuronal loss from the cerebral cortex.
Note Added in Proof. Since AD is a slowly progressive condition, the disorder of pyramidal neurons and a recent paper (31) emphasize the importance of a glycine site on pyramidal cells (as reviewed in ref. 6 ) by suggesting the basis for a rational pharmacological treatment before the disorder of these cells is as prominent as postmortem studies indicate.
